Previous close | 8.09 |
Open | 8.22 |
Bid | 8.13 x 200 |
Ask | 8.20 x 100 |
Day's range | 7.81 - 8.55 |
52-week range | 6.38 - 29.70 |
Volume | |
Avg. volume | 408,404 |
Market cap | 169.583M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -10.20 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.57 |
Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control - Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis - Patient Preference Survey: 88% of patients indicate
The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.